News & analysis on the clinical development and manufacture of large molecule drugs
Vir Biotechnology, Elliott Sigal
By Ben Hargreaves
- Last updated on
Vir Biotechnology brings Elliot Sigal onto its board of directors, adding his 25 years of experience in industry to the ‘guide the company’ to develop its pipeline.
For Sigal, it represents another addition to his roster of board and advisor positions, where he works with Surface Oncology, Amgen, Adaptimmune, Spark Therapeutics, Melanoma Research Alliance and New Enterprise Associates.
Sigal built his reputation as a member of Bristol Myers Squibb’s senior management team from 2001 to 2013, during which time the company brought through 14 new medicines. During 2004 to 2013, he held the position of chief scientific officer.
Regarding Sigal’s role, Vir’s CEO, George Scangos, outlined: “Sigal will work with the other members of Vir’s board to guide the company as we advance our development pipeline to treat and prevent serious infectious diseases.”
Vir’s work includes the development of siRNA treatments for hepatitis B, influenza, and COVID-19.